COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022

被引：14
|
作者：
Kislaya, Irina [1 ,2 ]
Machado, Ausenda [1 ,2 ]
Magalhaes, Sarah
Rodrigues, Ana Paula
Franco, Rafael
Leitek, Pedro Pinto [3 ,4 ]
Dias, Carlos Matias [1 ,2 ]
Nunes, Baltazar [1 ,2 ]
机构：
[1] Inst Nacl Sailde Doutor Ricardo Jorge, Dept Epidemiol, Lisbon, Portugal
[2] Univ NOVA Lisboa, Ctr Invest Saude Publ, Escola Nacl Saude Publ, Lisbon, Portugal
[3] Serv Partilhados Minist Saude, Lisbon, Portugal
[4] Direcao Servi Informacao & Analise, Direcao Geral Saude, Lisbon, Portugal
来源：
EUROSURVEILLANCE | 2022年 / 27卷 / 37期
关键词：
D O I：
10.2807/1560-7917.ES.2022.27.37.2200697
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In 2 80 year -olds, the second booster dose VE was 81% (95% CI: 75-85) and 82% (95% CI: 77-85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55-70) in 2 80 year -olds and 74% (95% CI: 66-80) in 60-79 year-olds against hospitalisation, and 63% (95% CI: 57-69) and 65% (95% CI: 54-74) against death.
引用
收藏
页数：6
相关论文
共 45 条
  • [21] Protection of COVID-19 Vaccination Against Hospitalization During the Era of Omicron BA.4 and BA.5 Predominance: A Nationwide Case-Control Study Based on the French National Health Data System
    Semenzato, Laura
    Botton, Jeremie
    Le Vu, Stephane
    Jabagi, Marie-Joelle
    Cuenot, Francois
    Drouin, Jerome
    Dray-Spira, Rosemary
    Weill, Alain
    Zureik, Mahmoud
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (10):
  • [22] Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥ 60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022-2023-2023
    Fabiani, Massimo
    Mateo-Urdiales, Alberto
    Sacco, Chiara
    Fotakis, Emmanouil Alexandros
    Battilomo, Serena
    Petrone, Daniele
    Del Manso, Martina
    Bella, Antonino
    Riccardo, Flavia
    Stefanelli, Paola
    Palamara, Anna Teresa
    Pezzotti, Patrizio
    VACCINE, 2024, 42 (23)
  • [23] COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study
    Whitaker, Heather J.
    Tsang, Ruby S. M.
    Byford, Rachel
    Aspden, Carole
    Button, Elizabeth
    Pillai, Praveen Sebastian
    Jamie, Gavin
    Kar, Debasish
    Williams, John
    Sinnathamby, Mary
    Marsden, Gemma
    Elson, William H.
    Leston, Meredith
    Anand, Sneha
    Okusi, Cecilia
    Fan, Xuejuan
    Linley, Ezra
    Rowe, Cathy
    Darcangelo, Silvia
    Otter, Ashley D.
    Ellis, Joanna
    Hobbs, F. D. Richard
    Tzortziou-Brown, Victoria
    Zambon, Maria
    Ramsay, Mary
    Brown, Kevin E.
    Amirthalingam, Gayatri
    Andrews, Nick J.
    de Lusignan, Simon
    Bernal, Jamie Lopez
    JOURNAL OF INFECTION, 2023, 87 (04) : 315 - 327
  • [24] Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study
    Jia, Siyue
    Yin, Zundong
    Pan, Hongxing
    Wang, Fuzhen
    Liu, Xiaoqiang
    Wang, Qing
    Zhang, Li
    Tang, Jihai
    Yang, Hao
    Du, Jiangbo
    Wang, Zhiguo
    Jin, Pengfei
    Peng, Zhihang
    Tang, Rong
    Kang, Guodong
    Wang, Xuewen
    Li, Simin
    Wang, Weixiao
    Li, Jingxin
    Shen, Hongbing
    Zhu, Fengcai
    EMERGING MICROBES & INFECTIONS, 2024, 13 (01)
  • [25] Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron
    Meeraus, Wilhelmine
    Postema, Abigail
    Gray, Christen M.
    Lee, Andrew
    Santa Maria, Andre
    Furtado, Barbara Emoingt
    Conde-Sousa, Eduardo
    Ouwens, Mario
    Valverde, Douglas Andreas
    Cunha, Clovis Arns da
    Barbosa, Alexandre Naime
    Corte, Claudia
    Taylor, Sylvia
    VACCINE, 2025, 53
  • [26] Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study
    Huiberts, Anne J.
    de Gier, Brechje
    Hoeve, Christina E.
    de Melker, Hester E.
    Hahne, Susan J. M.
    den Hartog, Gerco
    Grobbee, Diederick E.
    van de Wijgert, Janneke H. H. M.
    van den Hof, Susan
    Knol, Mirjam J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 133 : 36 - 42
  • [27] Pregnancy, fetal, and neonatal outcomes after a first booster dose of covid-19 vaccine during pregnancy in Ontario, Canada: population based, retrospective cohort study
    Fell, Deshayne B.
    Dimanlig-Cruz, Sheryll
    Toeroek, Eszter
    Haberg, Siri E.
    Regan, Annette K.
    Kaufman, Jay S.
    Platt, Robert W.
    Gravel, Christopher A.
    Bruce, Liam
    Shah, Prakesh S.
    Wilson, Kumanan
    Sprague, Ann E.
    Alton, Gillian D.
    Dhinsa, Tavleen
    El-Chaar, Darine
    Buchan, Sarah A.
    Kwong, Jeffrey C.
    Wilson, Sarah E.
    Dunn, Sandra, I
    Macdonald, Shannon E.
    Barrett, Jon
    Okun, Nannette
    Walker, Mark C.
    BMJ MEDICINE, 2023, 2 (01):
  • [28] COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study
    Tang, Fei
    Hammel, Iriana S.
    Andrew, Melissa K.
    Ruiz, Jorge G.
    LANCET HEALTHY LONGEVITY, 2022, 3 (09): : E589 - E598
  • [29] mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022
    Vitek, Marta Grgic
    Klavs, Irena
    Ucakar, Veronika
    Vrh, Marjana
    Mrzel, Maja
    Serdt, Mojca
    Fafangel, Mario
    EUROSURVEILLANCE, 2022, 27 (20)
  • [30] Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection: Repeat analyses with updated data for the prospective cohort study in the Netherlands from July 2021 to June 2022
    Huiberts, Anne J.
    van de Hof, Susan
    Knol, Mirjam J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024, 146
12345